BUZZ-Australia's NeuroScientific Biopharmaceuticals surges on positive clinical results** Shares of NeuroScientific Biopharmaceuticals NSB.AX rise as much as 52.2% to A$0.175, their highest level since September 24, 2025
** Biopharmaceutical co heading for best day since April 2025, if current gains hold
** Co announces successful clinical results from fistulising crohn's disease patients treated with its StemSmart mesenchymal stem cell therapy
** Says three of four patients demonstrated successful clinical response when treated with StemSmart
** About 4.3 mln shares change hands, 25.7x the 30-day average, in the busiest day since July 24, 2025
** Stock more than tripled in value last year
(Reporting by John Biju in Bengaluru)
((John.Biju@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.